Gain Therapeutics - Unfolding the next generation of allosteric small molecule therapies to meet patient needs
- Details
- Written by: web web
- Category: Home
- Hits: 2472
![pipeline-pic](/images/home/homepage-lead-program-image-cropped.png)
Gain’s lead drug candidate
is a best-in-class small molecule, for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases. is currently being evaluated in a Phase I clinical study.
Lead Program >>
- Details
- Written by: web web
- Category: Home
- Hits: 2896
By leveraging AI-supported 3D structural biology and supercomputer-powered proprietary physics-based models, Gain’s Magellan™ platform is able to identify novel allosteric binding sites on disease-implicated proteins and exploit their untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.
Our Platform >>
![magellan-logo](/images/home/magellan-logo.png)
- Details
- Written by: web web
- Category: Home
- Hits: 2441
![science-pic](/images/home/our science homepage.png)
ALLOSTERIC PROTEIN REGULATION
Our next generation allosteric small molecule therapeutics can modulate a protein to restore or disrupt function, not just through inhibition or activation, but also through stabilization, destabilization and degradation, based on disease pathology.
Our Science >>
- Details
- Written by: web web
- Category: Home
- Hits: 3116
July 2024
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Pha...
GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional...